UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment

Oct 7 (Reuters) - Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.